Pediatric Neurology
Volume 41, Issue 1 , Pages 57-58 , July 2009

Levetiracetam Induced Interstitial Nephritis and Renal Failure

  • Kathleen A. Hurwitz, MD

      Affiliations

    • Behavior and Development, Murrieta, California
    • Corresponding Author InformationCommunications should be addressed to: Dr. Hurwitz; Behavior and Development; 25395 Hancock, Suite 250; Murrieta, CA 92562.
    • ,
  • Elizabeth G. Ingulli, MD

      Affiliations

    • Department of Pediatrics, Rady Children's Hospital–San Diego, San Diego, California
    • Department of Pediatrics, UCSD School of Medicine, La Jolla, CA
    • ,
  • Henry F. Krous, MD

      Affiliations

    • Pathology Research SUDC Program, Rady Children's Hospital–San Diego, San Diego, California

Received 22 July 2008 ,Accepted 29 January 2009.

References 

  1. UCB Pharma Inc. Approved drug therapies. NDA 21–035. Levetiracetam. Revised Dec. 1, 1999. Available at: http://www.fda.gov/cder/foi/label/1999/21035lbl.pdf. Accessed July, 2008.
  2. Arroyo S, Crawford P. Safety profile on levetiracetam. Epileptic Disord. 2003;5(Suppl. 1):S57–S63
  3. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77–85
  4. Khurana DS, Kothare SV, Valencia I, Melvin JJ, Legido A. Levetiracetam monotherapy in children with epilepsy. Pediatr Neurol. 2007;36:227–230
  5. Bello-Espinosa LE, Roberts SL. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes: 3 cases. Seizure. 2003;12:157–159
  6. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet. 2004;43:707–724
  7. Hovinga CA. Levetiracetam: a novel antiepileptic drug. Pharmocotherapy. 2001;21:1375–1388
  8. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: Part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007;13:57–78
  9. Glauser TA, Ayala R, Elterman RD, et al. N159 Study Group Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006;66:1654–1660
  10. Choudhoury D, Ahmed A. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006;2:80–91
  11. Cruz DN, Perazella MA. Drug-induced acute tubulointerstitial nephritis: the clinical spectrum. Hosp Pract (Minneap). 1998;33:151–152152-8, 161-4
  12. Pastor-Milán E, Rubert-Gómez MA, Vázquez-Gutiérrez F, González V. Oxcarbazepine induced interstitial nephritis in a patient with drug hypersensitivity syndrome [In Spanish]. Rev Neurol. 2003;37:948–950
  13. Gogtay NJ, Bavdekar SB, Kshirsagar NA. Anticonvulsant hypersensitivity syndrome: a review. Expert Opin Drug Saf. 2005;4:571–581

PII: S0887-8994(09)00073-3

doi: 10.1016/j.pediatrneurol.2009.01.011

Pediatric Neurology
Volume 41, Issue 1 , Pages 57-58 , July 2009

Article Tools

* Image Usage & Resolution